For example, AS-IV promotes angiogenesis andimproves cerebral injury following cerebral ischemia by targetingthe SIRT7/VEGFA signaling pathway. Moreover,AS-IV targets AKT1 through the AKT1/GSK-3β signaling pathwayto attenuate kidney fibrosis. Furthermore,AS-IV inhibits PLA2 activity by targeting the catalytic triad of PRDX6,disrupting its interaction with RAC, which impedes NOX2 maturationand reduces oxidative stress damage. Thisstudy identified KHK as a novel target of AS-IV. The gene discussed is VEGFA; the disease is brain ischemia.